GoAI
Get started
Vor Biopharma Inc. logo

Vor Biopharma Inc.

VOR

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$23.36

+$0.295 · +1.28%

Aug 21, 3:55 PM ET

VOR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

45

Fair Value

Momentum

75

Gaining

Sentiment

48

Mixed

Risk resilience

28

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jean-Paul Kress
Listed since
Feb 5, 2021
Employees
76

Market position

Volume
618.16K
0.57× average
Average volume
1.09M
Average daily volume
Market cap
1.27B USD
Beta
1.72
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-264.36M USD
P/E (TTM)
-0.07×
P/B (TTM)
-6.34×
P/S (TTM)
0×
EV / EBITDA
0.38×
Earnings yield
-539.00%
Free cash flow yield
-111.25%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
423.57%
Return on assets
-149.96%
Return on invested capital
-84.61%

Financial health

Debt / equity
-0.01×
Current ratio
18.2×
Altman Z-score
2.47
Piotroski F-score
3 of 9

Financial statements

Income trends

Operating income

−371.64M USD-206.67%

Net income

−695.98M USD-495.29%
Income trends across reported periods−6.19M USD−257.02M USD−507.86M USD−758.69M USDOperating income, FY2021: −69.02M USDOperating income, FY2022: −93.42M USDOperating income, FY2023: −126.04M USDOperating income, FY2024: −121.19M USDOperating income, FY2025: −371.64M USDNet income, FY2021: −68.9M USDNet income, FY2022: −92.09M USDNet income, FY2023: −117.86M USDNet income, FY2024: −116.91M USDNet income, FY2025: −695.98M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −69.02M USD. Operating income FY2022 −93.42M USD. Operating income FY2023 −126.04M USD. Operating income FY2024 −121.19M USD. Operating income FY2025 −371.64M USD. Net income FY2021 −68.9M USD. Net income FY2022 −92.09M USD. Net income FY2023 −117.86M USD. Net income FY2024 −116.91M USD. Net income FY2025 −695.98M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold——3.49M USD8.96M USD—
Gross profit——−3.49M USD−8.96M USD—
Research and development321.53M USD93.31M USD94.32M USD64.55M USD47.53M USD
Selling, general, and administrative50.11M USD27.88M USD31.72M USD19.91M USD21.49M USD
Operating expenses371.64M USD121.19M USD122.54M USD84.46M USD69.02M USD
Interest income5.87M USD4.27M USD8.17M USD1.32M USD119K USD
Depreciation and amortization2.89M USD3.53M USD3.49M USD8.96M USD1.43M USD
Operating income−371.64M USD−121.19M USD−126.04M USD−93.42M USD−69.02M USD
Net income−695.98M USD−116.91M USD−117.86M USD−92.09M USD−68.9M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
18%
2 beats, 8 misses, 1 met estimate
Average EPS surprise
-916.42%
11 comparable reports
Latest EPS result
-1.16
Estimate -0.86 · Miss by 35.40%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates68.16-46.18-160.52-274.86Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual -8.8, estimate -0.34, surprise -2488.24%, Miss. Q2 2025, reported May 15, 2025: actual -5.2, estimate -5, surprise -4.00%, Miss. Q3 2025, reported Aug 12, 2025: actual -251.2, estimate -11.4, surprise -2103.51%, Miss. Q4 2025, reported Nov 13, 2025: actual -121.63, estimate -3.06, surprise -3874.84%, Miss. Q1 2026, reported Mar 30, 2026: actual 44.5, estimate -1.14, surprise +4003.51%, Beat. Q2 2026, reported May 13, 2026: actual -0.73, estimate -0.75, surprise +2.67%, Beat. Q3 2026, reported Aug 11, 2026: actual -1.16, estimate -0.857, surprise -35.40%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.81, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$29.00

24.14% upside
Past 12 months12-month forecastHigh $31.00Average $29.00Low $27.00

Rating distribution

13 ratings
Strong buy00%
Buy1077%
Hold323%
Sell00%
Strong sell00%

Recent analyst actions

8 institutions
JP MorganmaintainOverweight
BarclaysmaintainOverweight

VOR news

globenewswire.com

Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary…

Read source
globenewswire.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on August 1, 2026, the Compensation…

Read source
globenewswire.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on August 1, 2026, the Compensation…

Read source
globenewswire.com

Vor Bio Appoints David Zaccardelli to Board of Directors

BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D.,…

Read source
seekingalpha.com

Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes

Vor Biopharma (VOR) has transformed into a late-stage autoimmune drug developer, focusing on telitacicept, a dual BAFF/APRIL inhibitor with multiple China approvals. VOR holds $491.5 million in cash, providing runway…

Read source
globenewswire.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on July 1, 2026, the Compensation Committee…

Read source

Corporate actions

Corporate action history

Stock split

Effective Sep 19, 2025

1:20

VOR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding VOR

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
42.52M
Weight
0.37%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
32.8M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
23.98M
Weight
0.03%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
10.42M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
6.09M
Weight
0.04%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
4.84M
Weight
0.03%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
3.24M
Weight
0.21%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.7M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%

Continue in GoAI

Research VOR

research.disclaimer